Overview
Lobbying Costs
150,000€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
0.75 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
BioNTech SE
EU Transparency Register
516273537966-42 First registered on 04 May 2020
Goals / Remit
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
Main EU files targeted
Interactions with the European Commission and the European Investment Bank regarding activities relating to mRNA drugs and vaccines, including financial support for increasing manufacturing capacity of such drugs and vaccines.
Address
Head Office
An der Goldgrube 12
Mainz 55131
GERMANY -
People
Total lobbyists declared
3
Employment time Lobbyists 25% 3 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 16 May 2021
Name Start date End Date Ana PANCHEVSKA 12 Jan 2024 10 Jan 2025 Constanze BLUME 12 Jan 2024 10 Jan 2025 Ms Ana Panchevska 12 Jan 2024 15 Apr 2024 Ms Constanze BLUME 12 Jan 2024 15 Apr 2024 Complementary Information
N/A
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Bio Deutschland e.V.
BME e.V.
Gesundheitswirtschaft Rhein-Main e.V.
Research Quality Association Ltd
DIRK - Deutscher Investor Relations Verband e.V.
CI3 e.V.
Mainzer Wissenschaftsallianz e.V.
Verband Forschender Arzneimittelhersteller e.V.
IHK - Industrie- und Handelskammer für Rheinhessen
Kita BioRegio e. V.Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
150,000€
EU grant income for closed financial year
100,000,000 € (Source: EIB loan)
Other financial info
N/A
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
N/A
Other activities
N/A
Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 22 Feb 2024 Location online Subject Presentation of their global health activities DG Directorate-General for International Partnerships Attending - Koen Doens (Director-General)
-
Date 27 Jun 2023 Location Brussels Subject social Europe, skills, industrial strategy Cabinet Cabinet of Commissioner Nicolas Schmit Portfolio Jobs and Social Rights Attending - Christoph Nerlich (Cabinet member)
-
Date 06 Jan 2022 Location Videoconference Subject Meeting with CEO of BioNTech Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
-
Date 06 May 2021 Location Marburg Germany Subject Site visit and assessment of production capacity and supply chain Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 31 Jan 2021 Location Videoconference Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists